{
    "clinical_study": {
        "@rank": "55436", 
        "arm_group": {
            "arm_group_label": "Open-label gabapentin", 
            "arm_group_type": "Experimental", 
            "description": "Dose titration of 100mg for 1 week, 300mg for 3 weeks, and 600mg for 3 weeks."
        }, 
        "brief_summary": {
            "textblock": "The broad goal of this study is to obtain pilot data to determine the tolerability and\n      preliminary efficacy of the non-hormonal agent gabapentin for insomnia symptoms and\n      nighttime Vasomotor Symptoms (VMS) when open-label gabapentin is administered at low dose\n      and only at night in peri- and postmenopausal women. We hypothesize that the majority of\n      participants will be able to increase and tolerate treatment, and insomnia symptoms and the\n      frequency of nighttime VMS will improve on low-dose gabapentin dosed at bedtime."
        }, 
        "brief_title": "Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms in Peri- and Postmenopausal Women", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Menopause", 
            "Hot Flashes", 
            "Vasomotor Disturbance"
        ], 
        "condition_browse": {
            "mesh_term": "Hot Flashes"
        }, 
        "detailed_description": {
            "textblock": "Twenty-five peri- and postmenopausal women at the Boston sites (MGH and BWH) will be\n      enrolled into this open-label pilot study. This will be a 7-week intervention study using\n      open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week,\n      followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.  The intervention study will\n      follow a 3-week screening period to establish a stable baseline for insomnia symptoms and\n      VMS and to determine the safety of administering gabapentin in study participants.\n      Tolerability and treatment response (insomnia symptoms, nighttime VMS) will be assessed\n      systematically at each study visit.  The dose titration schedule will be followed in all\n      participants unless there are dose-limiting toxicities."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Females aged 40-65 years\n\n          2. Postmenopausal or perimenopausal\n\n          3. Having bothersome hot flashes\n\n          4. Having some bothersome hot flashes during the night\n\n          5. Insomnia or problems sleeping\n\n          6. In general, good health\n\n          7. Signed informed consent\n\n        Exclusion Criteria:\n\n          1. Recent use of hormone therapy or hormonal contraceptives (with the exception of the\n             Mirena IUD)\n\n          2. Recent use of any prescribed therapy that is taken specifically for hot flashes\n\n          3. Recent use of any over-the-counter or herbal therapies that are taken specifically\n             for hot flashes\n\n          4. Recent use of any prescribed medications with known hot flash efficacy\n\n          5. Known hypersensitivity or contraindications (reasons not to take) to gabapentin\n\n          6. Not using a medically approved method of birth control, if sexually active and not 12\n             or more months since last menstrual period\n\n          7. Recent drug or alcohol abuse\n\n          8. Lifetime diagnosis of psychosis or bipolar disorder\n\n          9. Suicide attempt in the past 3 years or any current suicidal ideation\n\n         10. Current major depression (assessed during screening)\n\n         11. Pregnancy, intending pregnancy, or breast feeding\n\n         12. History of:\n\n               1. Renal insufficiency or a kidney disorder\n\n               2. Sleep disorder diagnosis of sleep apnea, restless legs syndrome, periodic limb\n                  movement disorder, or narcolepsy\n\n         13. Any unstable medical condition\n\n         14. Working a night/rotating shift\n\n         15. Abnormal screening blood tests\n\n         16. Current participation in another drug trial or intervention study\n\n         17. Inability or unwillingness to complete the study procedures"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040532", 
            "org_study_id": "2013P002196", 
            "secondary_id": "5U01AG032700-05"
        }, 
        "intervention": {
            "arm_group_label": "Open-label gabapentin", 
            "description": "The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.", 
            "intervention_name": "Gabapentin", 
            "intervention_type": "Drug", 
            "other_name": "Neurontin"
        }, 
        "intervention_browse": {
            "mesh_term": "Gabapentin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "contact": {
                    "email": "adavies2@partners.org", 
                    "last_name": "Abigail Davies", 
                    "phone": "617-724-6540"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": {
                    "last_name": "Lee S Cohen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "skim69@partners.org", 
                    "last_name": "Semmie Kim", 
                    "phone": "617-525-6459"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02116"
                    }, 
                    "name": "Brigham and Women's Hospital"
                }, 
                "investigator": {
                    "last_name": "Hadine Joffe, MD, MSc", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Study to Assess Tolerability and Preliminary Efficacy of a Titrated Dose of Gabapentin up to 600mg Administered at Bedtime for Insomnia Symptoms and Nighttime Vasomotor Symptoms in Peri- and Postmenopausal Women With Vasomotor Symptoms", 
        "other_outcome": [
            {
                "description": "Measured by self-report responses to questionnaires", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "7 weeks"
            }, 
            {
                "description": "Measured by self-report responses to questionnaires", 
                "measure": "Pain", 
                "safety_issue": "No", 
                "time_frame": "7 weeks"
            }
        ], 
        "overall_contact": {
            "email": "adavies2@partners.org", 
            "last_name": "Abigail Davies", 
            "phone": "617-724-6540"
        }, 
        "overall_contact_backup": {
            "email": "skim69@partners.org", 
            "last_name": "Semmie Kim", 
            "phone": "617-525-6459"
        }, 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Lee S Cohen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Measured by self-report responses to questionnaires", 
                "measure": "Tolerability of gabapentin", 
                "safety_issue": "No", 
                "time_frame": "7 weeks"
            }, 
            {
                "description": "Measured by self-report VMS diaries twice daily.", 
                "measure": "VMS frequency, severity, and bothersomeness", 
                "safety_issue": "No", 
                "time_frame": "7 weeks"
            }, 
            {
                "description": "Measured by self-report responses to questionnaires at week 4 and week 7, and daily self-report sleep diary.", 
                "measure": "Subjective sleep quality", 
                "safety_issue": "No", 
                "time_frame": "7 weeks"
            }
        ], 
        "reference": [
            {
                "PMID": "22433978", 
                "citation": "Ensrud KE, Joffe H, Guthrie KA, Larson JC, Reed SD, Newton KM, Sternfeld B, Lacroix AZ, Landis CA, Woods NF, Freeman EW. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause. 2012 Aug;19(8):848-55."
            }, 
            {
                "PMID": "20035910", 
                "citation": "Joffe H, Petrillo L, Viguera A, Koukopoulos A, Silver-Heilman K, Farrell A, Yu G, Silver M, Cohen LS. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol. 2010 Feb;202(2):171.e1-171.e11. doi: 10.1016/j.ajog.2009.10.868. Epub 2009 Dec 24."
            }, 
            {
                "PMID": "17138773", 
                "citation": "Soares CN, Joffe H, Rubens R, Caron J, Roth T, Cohen L. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol. 2006 Dec;108(6):1402-10."
            }, 
            {
                "PMID": "19708803", 
                "citation": "Yurcheshen ME, Guttuso T Jr, McDermott M, Holloway RG, Perlis M. Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring model. J Womens Health (Larchmt). 2009 Sep;18(9):1355-60. doi: 10.1089/jwh.2008.1257."
            }, 
            {
                "PMID": "17917611", 
                "citation": "Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause. 2008 Mar-Apr;15(2):310-8."
            }, 
            {
                "PMID": "16139656", 
                "citation": "Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, Sweeney TJ, Banerjee TK, Flynn PJ. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005 Sep 3-9;366(9488):818-24."
            }, 
            {
                "PMID": "16816054", 
                "citation": "Reddy SY, Warner H, Guttuso T Jr, Messing S, DiGrazio W, Thornburg L, Guzick DS. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol. 2006 Jul;108(1):41-8."
            }, 
            {
                "PMID": "20050764", 
                "citation": "Aguirre W, Chedraui P, Mendoza J, Ruilova I. Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes. Gynecol Endocrinol. 2010 May;26(5):333-7. doi: 10.3109/09513590903511539."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040532"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Lee S. Cohen, MD", 
            "investigator_title": "Director, Center for Women's Mental Health", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Measured by self-report responses to questionnaires", 
                "measure": "Anxiety", 
                "safety_issue": "No", 
                "time_frame": "7 weeks"
            }, 
            {
                "description": "Measured by self-report responses to questionnaires", 
                "measure": "Depressed mood", 
                "safety_issue": "No", 
                "time_frame": "7 weeks"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Brigham and Women's Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Institute on Aging (NIA)", 
                    "agency_class": "NIH"
                }
            ], 
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}